Trial of Miltuximab in Prostate, Other Cancers Gets Nod to Enroll Additional Patients

Trial of Miltuximab in Prostate, Other Cancers Gets Nod to Enroll Additional Patients
The first-in-human clinical trial assessing the safety and tolerability of Miltuximab (MIL-38) — a radiolabeled antibody designed to image prostate, bladder, and pancreatic cancer — is proceeding to its second part, according to Minomic International. Miltuximab is a chimeric version of Minomic’s MIL-38 antibody, linked to the radioactive isotope Gallium-67. A chimeric antibody is one that includes human and mouse parts, which ensures the patient's immune system does not recognize and reject the antibody as foreign. The antibody is directed against Glypican-1 (GPC-1), a protein which has been found to be over-expressed in multiple kinds of cancer, including esophageal cancer and gliobastoma. In preclinical studies, it has shown strong r
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *